Walleye Trading’s Passage Bio PASG Stock Holding History

Walleye Trading’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,220	Closed	-$323K	–	5574
2021 Q2	$323K	Buy	+1,220	New	+$377K	﹤0.01%	3412

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Walleye Trading's PASG Position: Q3 2021 in Review

Walleye Trading sold out of Passage Bio (PASG) in Q3 2021, closing a stake of 1,220 shares — an estimated $323K sold.

Walleye Trading first reported a position in PASG in Q2 2021 and held it in 1 quarter. The position peaked at $323K in Q2 2021. 101 funds tracked by Wall St. Rank hold PASG as of Q3 2021.

Walleye Trading reported no remaining Passage Bio position as of Q3 2021 after selling out during the quarter.
Walleye Trading sold 1,220 Passage Bio shares in Q3 2021, an estimated $323K.
Walleye Trading first reported a position in Passage Bio in Q2 2021 and held it in 1 quarter.
Walleye Trading's Passage Bio position peaked at $323K in Q2 2021.
101 funds tracked by Wall St. Rank held Passage Bio as of Q3 2021.

Based on Walleye Trading's 13F filing for Q3 2021, filed 15 Nov 2021.